News and Trends 16 Nov 2016 Meet the CEO making the Next Generation of Gene Therapies Possible How do you solve a problem like lentiviral vector infections? CEVEC has done it. We sat down with the CEO, Frank Ubags, to talk about his company’s success. The last few decades have not been kind to gene therapy companies, but the field seems to be on the edge of a renaissance with adenoviral vectors […] November 16, 2016 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 16 Nov 2016 Cell Therapies: Is Commercialization holding back a Breakthrough? How far away is biotech from a breakthrough with cell and gene therapy? While these therapies have the potential to be the most effective on the market, they are still a long way away from that point, according to a pair of expert panels at BIO Europe last week. Everyone in cell therapy knows the […] November 16, 2016 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2016 RNAi Therapy is Back: Sanofi is firmly on board to treat Hemophilia Sanofi Genzyme is offering Alnylam up to €93M ($100M) to co-develop and launch a revolutionary RNAi therapy for hemophilia. But is RNAi really such a good investment? Sanofi Genzyme signed a deal with Alnylam back in 2014 to develop RNAi therapies. Now, despite the general discouragement in RNAi technology, Sanofi has decided to go ahead and […] November 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2016 CRISPR meets RNAi: a whole new Targeted Therapy Silence Therapeutics just announced preclinical data for a novel CRISPR therapy targeted to the liver using its RNAi delivery expertise. How does it plan to find a space in this challenging and competitive field? Based on the UK’s golden triangle, Silence Therapeutics develops RNAi therapies to treat cancer. Now, it will be applying its targeted RNA delivery […] November 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2016 Red Blood Cells as Cancer Drug Carriers: Market Approval gets Delayed Erytech will have to provide additional data before re-applying for market approval in Europe for Graspa. This leukemia therapy uses red blood cells to deliver an enzyme that starves tumors to death. Erytech is a biotech from Lyon with a visionary approach to treat cancer: using red blood cells as drug carriers. Last year, the company […] November 15, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2016 How much of a Gamble is Investing in CRISPR? CRISPR is going to change a lot in the life science industry and is perceived as THE discovery of the 21st century. Within the past 6 months, 3 companies went public, raising between €50M and €100M each (with valuation close to the billion), to bring about the CRISPR revolution. But the problem is, there is absolutely […] November 15, 2016 - 4 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2016 Ask the Biotech Recruiter: Time-Saving Tricks to Reel in a New Hire Time is of the essence in a recruitment. The biotech recruiters at Pact & Partners know how to manage it efficiently without missing anything! Hiring a top talent is an exhausting and time-consuming process, and it can be tempting to rush through it once you think you’ve found a match. But this attitude can create more […] November 14, 2016 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2016 Meet one of the Most Impressive French Biotech Entrepreneurs The previous executive profiles we did, namely on Joern Aldag and Philippe Dro, are hard acts to follow, but Bernard Gilly was more than up to it. Bernard has a broad set of achievements for a broad set of lessons and takeaways. Here are the major ones. You might have seen Bernard Gilly’s name in the […] November 14, 2016 - 6 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2016 USB key Diagnostic could help manage HIV Treatment Anywhere A new method of gene sequencing has brought us an HIV diagnostic on a “USB stick”, which determines the levels of the virus with one drop of blood and in under 30 minutes. Once perfected, the technology could be the tool for HIV management as glucose meters are for diabetes. While pharma and research work […] November 14, 2016 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 12 Nov 2016 The sound of this Spider Silk Violin surprises Expert Musicians Last week, Imperial College London hosted the International Student Innovation Awards. The winner astonished everyone with a violin made with spider silk. Luca Alessandrini was awarded the £10,000 prize for the design of a biomaterial-based violin that can be engineered to customize the final sound. With the new funds and a patent filed, the designer is now looking for co-founders to […] November 12, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2016 UPDATE: FDA Lifts Hold on Adaptimmune’s Rare Cancer Trials The FDA puts one of Adaptimmune‘s TCR trials on a partial hold, pending more information about the production of its cell therapy. It’s more waves for the Biotech’s financial rocking boat. Oxford-based Adaptimmune is one of the European players in TCR therapies. Besides being listed on the NASDAQ, it got GSK on board on a €311M […] November 10, 2016 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2016 Evotec chooses Oxford as Proving Ground for Academia-Industry Bridge The German CRO has struck a deal with the University of Oxford to test a model framework for bringing academic research to the clinic faster. Evotec started out as a service provider in Hamburg, but thanks to former CEO Jörn Aldag, it has blossomed into a company that specializes in transforming newly discovered therapies into […] November 10, 2016 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email